Celgene

Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Motley Fool
Celgene
Editas Medicine
Juno Therapeutics
CRISPR
gene editing
Flag link:
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
ozanimod
liso-cel
bb2121
Flag link:
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
Stat
Bristol-Myers Squibb
Celgene
Pharma CEOs
Giovanni Caforio
Merck
M&A
Flag link:
Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla
Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla
Fierce Pharma
Amgen
Otezla
Celgene
psoriasis
Flag link:
Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene
Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene
Pharmaceutical Business Review
M&A
Bristol-Myers Squibb
Celgene
Flag link:
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much
Fierce Pharma
earnings
Big Pharma
AstraZeneca
Merck
Celgene
Novartis
Novo Nordisk
Pfizer
Flag link:
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Investors Business Daily
Bristol-Myers Squibb
Celgene
FTC
M&A
Flag link:
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Endpoints
Editas Medicine
Celgene
Juno Therapeutics
CRISPR
gene editing
immunotherapy
Flag link:
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Biopharma Dive
ASH
Celgene
M&A
Bristol-Myers Squibb
liso-cel
Flag link:
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
BioSpace
Celgene
Acceleron
Reblozyl
anemia
beta thalassemia
Flag link:
Celgene posts pivotal CAR-T data ahead of FDA filing
Celgene posts pivotal CAR-T data ahead of FDA filing
Fierce Biotech
Celgene
CAR-T
liso-cel
Kymriah
Yescarta
Flag link:
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Adamis Pharmaceuticals
Redhill Biopharma
Amag Pharmaceuticals
Arqule
Agile Therapeutics
Agios Pharmaceuticals
Deciphera
Mirati Therapeutics
Sutro BioPharma
Merck
Pfizer
Amgen
EXACT Sciences
Bristol-Myers Squibb
Celgene
Oyster Point Pharma
Flag link:
Factors Setting the Tone for Celgene (CELG) Q3 Earnings
Factors Setting the Tone for Celgene (CELG) Q3 Earnings
Yahoo/Zacks.com
Celgene
earnings
Flag link:
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation
Yahoo/Businesswire
Bristol-Myers Squibb
Celgene
M&A
Flag link:
A change of the guard for the world’s biggest cancer companies
A change of the guard for the world’s biggest cancer companies
EP Vantage
cancer
Bristol-Myers Squibb
Celgene
M&A
Roche
AstraZeneca
Flag link:
As Celgene becomes BMS, its I&I lead lands CEO job at Takeda spinoff
As Celgene becomes BMS, its I&I lead lands CEO job at Takeda spinoff
Fierce Biotech
Celgene
Bristol-Myers Squibb
M&A
Terrie Curran
Phathom
Flag link:
3 Biotechs With the Biggest Cash Stockpiles
3 Biotechs With the Biggest Cash Stockpiles
Motley Fool
biotech
cash
Gilead Sciences
Amgen
Celgene
Flag link:
Roche and Celgene set for battle in acute myelogenous leukaemia
Roche and Celgene set for battle in acute myelogenous leukaemia
EP Vantage
Celgene
Roche
AML
acute myeloid leukemia
CC-486
Venclexta
Flag link:
Celgene's AML drug clears late-stage test
Celgene's AML drug clears late-stage test
Endpoints
Celgene
AML
CC-486
acute myeloid leukemia
Flag link:
Celgene's phase 3 AML test chalks up a win
Celgene's phase 3 AML test chalks up a win
Fierce Biotech
Celgene
acute myeloid leukemia
CC-486
clinical trials
Flag link:

Pages